GLP1R and colorectal cancer: In a meta-analysis of five studies that included over 2 million people, colorectal cancer risk was significantly lower in people using GLP-1R agonists compared with those using TZDs, SGLT2 inhibitors, and insulin, and was equivalent to that in people using sulfonylureas, metformin, or DPP4 inhibitors (23).